Absci, known for its innovative AI antibody discovery, is teaming up with AstraZeneca, a big player in biopharmaceuticals. This dynamic duo aims to use the power of AI to find groundbreaking cancer treatments.
In this cool partnership, Absci’s Founder & CEO, Sean McClain, is excited to join forces with AstraZeneca, a heavyweight in oncology. Their mission? Speeding up the discovery of a potential game-changing cancer therapy.
Absci’s Integrated Drug Creation platform, a mix of AI and lab technologies, is at the heart of this collaboration. AstraZeneca, represented by Puja Sapra, PhD, SVP of Biologics Engineering & Oncology Targeted Delivery, brings its top-notch oncology expertise to the table.
In simple terms, Absci, led by Sean McClain, will use its fancy AI tech to craft a special antibody for a specific cancer target. This partnership involves upfront commitment, solid R&D funding, and even royalties on future sales.
Sean McClain is thrilled about working with AstraZeneca, a leader in developing novel oncology treatments. Their aim is clear: design an antibody that can make a real difference for cancer patients.
Absci’s Integrated Drug Creation platform mixes AI and lab technologies, generating unique data that powers Absci’s AI models. These models help design antibodies, validated through lab experiments—a speedy approach completing the cycle in about six weeks.
Puja Sapra, sees this collaboration as an exciting opportunity to use Absci’s AI antibody creation platform for a potential new oncology therapy.
This news follows Absci’s recent breakthrough in designing antibodies using their state-of-the-art ‘zero-shot’ generative AI model.
The collaboration between Absci, led by CEO Sean McClain, and AstraZeneca, represented by Puja Sapra, PhD, shows how AI can revolutionize drug discovery. Exciting times lie ahead as these industry leaders combine forces to push the boundaries of what AI can achieve in cancer treatment development.
